Masaru Matsuda sold $43k of ARQT
See Remarks at Arcutis Biotherapeutics, Inc.. 3,263 shares at an average of $13.03, traded Mar 3, 2025, filed Mar 4, 2025.
Score components
- +15RoleOfficer
- +6Trade size$43k at market
- 0Share of holdings soldSold 1.5% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001787306-25-000038, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 28, 2025 | AGrant or award Common Stock10b5-1 | +34,000 | $0.00 | $0 | 212,692 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -3,263 | $13.03 | $43k | 209,429 | Mar 4, 2025 |
| Feb 28, 2025 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +89,000 | $0.00 | $0 | 89,000 | Mar 4, 2025 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 12Weak | sell 210b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k | 3,674 | |
| 3Weak | sell 210b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k | 4,730 | |
| 16Weak | sell 210b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k | 9,989 | |
| 11Weak | sell 210b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Todd Franklin Watanabe See Remarks | $64k | 3,671 | |
| 10Weak | sell 410b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Todd Franklin Watanabe See Remarks | $21k | 1,200 | |
| 29Weak | sell 410b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $921k | 61,403 | |
| 21Weak | sell 410b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $130k | 10,000 | |
| 25Weak | sell 410b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Todd Franklin Watanabe See Remarks | $327k | 25,015 | |
| 17Weak | sell 410b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $49k | 3,773 | |
| 15Weak | sell 510b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Larry Todd Edwards See Remarks | $28k | 2,173 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.